03:42 AM EST, 11/18/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Sunday its phase 1 study of nucresiran as a potential treatment for transthyretin amyloidosis showed the drug's efficacy.

Transthyretin amyloidosis is a condition characterized by the buildup of abnormal protein deposits in the body's organs and tissues.

The results showed that a single dose of the drug reduced transthyretin protein levels by more than 90% at day 15 and more than 70% after 360 days, with nucresiran being well tolerated at all tested doses, the company said.

Alnylam plans to share phase 3 testing plans in Q1.

Price: 235.88, Change: +0.32, Percent Change: +0.14